Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Grows By 323.2%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 187,900 shares, a growth of 323.2% from the February 28th total of 44,400 shares. Based on an average daily volume of 830,400 shares, the days-to-cover ratio is currently 0.2 days. Currently, 7.5% of the shares of the company are sold short.

Institutional Investors Weigh In On ZyVersa Therapeutics

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Virtu Financial LLC bought a new position in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned 1.08% of ZyVersa Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 3.91% of the company’s stock.

ZyVersa Therapeutics Price Performance

Shares of NASDAQ ZVSA opened at $0.73 on Thursday. The stock has a fifty day simple moving average of $1.13 and a two-hundred day simple moving average of $1.48. ZyVersa Therapeutics has a 1-year low of $0.69 and a 1-year high of $8.40.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.